Drug Profile


Alternative Names: Allogenic mesenchymal cell therapy - Apceth

Latest Information Update: 23 Apr 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Apceth
  • Class Gene therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Graft-versus-host disease
  • Preclinical Inflammation

Most Recent Events

  • 02 Apr 2015 Clinical trials in Graft-versus-host disease in Germany (Parenteral) before April 2015
  • 02 Apr 2015 Preclinical trials in Inflammation in Germany (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top